نتایج جستجو برای: braf

تعداد نتایج: 7505  

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2017
Atul Kulkarni Husam Al-Hraishawi Srilatha Simhadri Kim M Hirshfield Suzie Chen Sharon Pine Chandrika Jeyamohan Levi Sokol Siraj Ali Man Lung Teo Eileen White Lorna Rodriguez-Rodriguez Janice M Mehnert Shridar Ganesan

Purpose: Many patients with BRAFV600E mutant melanoma treated with BRAF inhibitors experience a rapid response, but ultimately develop resistance. Insight into the mechanism of resistance is critical for development of more effective treatment strategies.Experimental Design: Comprehensive genomic profiling of serial biopsies was performed in a patient with a BRAFV600E mutant metastatic melanoma...

2012
Gholamreza Safaee Ardekani Seyed Mehdi Jafarnejad Larry Tan Ardavan Saeedi Gang Li

BACKGROUND Mutation of BRAF is a predominant event in cancers with poor prognosis such as melanoma and colorectal cancer. BRAF mutation leads to a constitutive activation of mitogen activated protein kinase pathway which is essential for cell proliferation and tumor progression. Despite tremendous efforts made to target BRAF for cancer treatment, the correlation between BRAF mutation and patien...

2012
Nicola L. Schoenewolf Reinhard Dummer Daniela Mihic-Probst Holger Moch Mathew Simcock Adrian Ochsenbein Silke Gillessen Peter Schraml Roger von Moos

BACKGROUND Melanoma is characterized by a high frequency of BRAF mutations. It is unknown if the BRAF mutation status has any predictive value for therapeutic approaches such as angiogenesis inhibition. PATIENTS AND METHODS We used 2 methods to analyze the BRAF mutation status in 52 of 62 melanoma patients. Method 1 (mutation-specific real-time PCR) specifically detects the most frequent BRAF...

2017
Antonio M Grimaldi Ester Simeone Lucia Festino Vito Vanella Paolo A Ascierto

A cquired resistance is the most common cause of BRAF inhibitor monotherapy treatment failure, with the majority of patients experiencing disease progression with a median progression-free survival of 6-8 months. As such, there has been considerable focus on combined therapy with dual BRAF and MEK inhibition as a means to improve outcomes compared with monotherapy. In the COMBI-d and COMBI-v tr...

2015
Hillary Z. Kimbrell Andrew B. Sholl Swarnamala Ratnayaka Shanker Japa Michelle Lacey Gandahari Carpio Parisha Bhatia Emad Kandil

BACKGROUND BRAF V600E mutation is associated with poor prognosis in patients with papillary thyroid carcinoma (PTC). PTC is often multifocal, and there are no guidelines on how many tumors to test for BRAF mutation in multifocal PTC. METHODS Fifty-seven separate formalin-fixed and paraffin-embedded PTCs from twenty-seven patients were manually macrodissected and tested for BRAF mutation using...

2017
Payal Jain Amanda Silva Harry J. Han Shih-Shan Lang Yuankun Zhu Katie Boucher Tiffany E. Smith Aesha Vakil Patrick Diviney Namrata Choudhari Pichai Raman Christine M. Busch Tim Delaney Xiaodong Yang Aleksandra K. Olow Sabine Mueller Daphne Haas-Kogan Elizabeth Fox Phillip B. Storm Adam C. Resnick Angela J. Waanders

Pediatric low-grade gliomas (PLGGs) are frequently associated with activating BRAF gene fusions, such as KIAA1549-BRAF, that aberrantly drive the mitogen activated protein kinase (MAPK) pathway. Although RAF inhibitors (RAFi) have been proven effective in BRAF-V600E mutant tumors, we have previously shown how the KIAA1549-BRAF fusion can be paradoxically activated by RAFi. While newer classes o...

2015
Eleonora Monti Michela Bovero Lorenzo Mortara Giorgia Pera Simonetta Zupo Elena Gugiatti Mariella Dono Barbara Massa Gian Luca Ansaldo Giusti Massimo

Background. Molecular diagnostics has offered new techniques for searching for mutations in thyroid indeterminate lesions. The study's aim was to evaluate the BRAF mutations' incidence in an Italian regional population. Subjects and Methods. 70 Caucasian patients born in Liguria with indeterminate or suspicious cytological diagnoses. Results. A BRAF gene mutation was successfully analyzed in 56...

Journal: :JAMA oncology 2015
Jorge D Ramos Evan Y Yu

tation status) on objective response rates with nivolumab, although this difference was not observed in the overall data analysis reported by Larkin et al. 1 Furthermore, while there are data to suggest synergy between BRAF-directed therapy and PD-1 blockade (an area of active investigation, although not approved for clinical use), current data do not support clear differences in clinical respo...

2018
Parham Jabbarzadeh Kaboli Patimah Ismail King-Hwa Ling

RAF kinases are a family of enzymes in the MAP kinase pathway that contribute to the development of different types of cancer. BRAF is the most important member of RAF kinases. BRAF mutations have been detected in 7% of all cancers and 66% of melanomas; as such, the FDA has approved a few BRAF inhibitor drugs to date. However, BRAF can activate CRAF leading to resistance to BRAF inhibitors. Ber...

Journal: :Cancer research 2010
Andrea Boni Alexandria P Cogdill Ping Dang Durga Udayakumar Ching-Ni Jenny Njauw Callum M Sloss Cristina R Ferrone Keith T Flaherty Donald P Lawrence David E Fisher Hensin Tsao Jennifer A Wargo

Targeted therapy against the BRAF/mitogen-activated protein kinase (MAPK) pathway is a promising new therapeutic approach for the treatment of melanoma. Treatment with selective BRAF inhibitors results in a high initial response rate but limited duration of response. To counter this, investigators propose combining this therapy with other targeted agents, addressing the issue of redundancy and ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید